Please assess the completion status of the following clinical trial:

Trial Title: Echinacea Angustifolia (AnxioCalm) in Anxiety

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women 18 years of age (all races and ethnicity)~* Meet Diagnostic and Statistical Manual of Mental Disorders (DSM IV) any criteria for Generalized Anxiety Disorder (GAD from 5 to 9)~* mild to moderate symptom severity on the Beck Anxiety Inventory (BAI from 8 to 15)~* Hamilton Anxiety Rating Scale (HAM-A) score from 14 to 17~* Hospital Anxiety and Depression Scale (HADS-A) \[hospital anxiety and depression scale - anxiety subscale\] - 8-10~* Participants score 45-57 points of above on either the state or trait anxiety subscale of the State and Trait Anxiety Inventory of Speilberger (STAI)~* Able to understand and provide signed informed consent~* Able to participate in a 5-week study~Exclusion Criteria:~* Any diagnosed DSM-IV Axis II disorder~* Current DSM IV Axis I diagnosis of Major Depressive Disorder in the 6 month that precede the study. \[to exclude confounding psychiatric factors\]~* Danger of suicidality~* Treatment with Echinacea preparations in the 3 month that precede the study~* Psychotropic medication (especially anxiolytics) in the 3 month that precede the study~* Psychotherapy in the 3 month that precede the study~* Allergic reactions to plants of the Asteraceae family (Echinacea species, etc.)~* Treatment for AIDS or cancer~* Pregnant or lactating women~* Unstable medical condition (e.g., hypothyroidism, hypertension, myocardial infarction within 1 month, neoplastic condition)~* Alcohol or drug dependence within 3 months~* Allergy to Echinacea preparation~* Allergy to plants of the Asteraceae family (e.g., ragweed, asters, chrysanthemum)~* Allergy to mugwort, radioallergosorbent test (RAST), or birch tree pollen Concurrent tranquilizer, antidepressant or mood stabilizer therapy;~* Subjects receiving anti-anxiety medication (e.g., benzodiazepine, venlafaxine, buspirone, or SSRI)~* Concurrent use of over-the-counter anti-anxiety and/or antidepressant preparations (e.g., chamomile, St. John's Wort, Kava kava)~* Women of child-bearing potential not willing to employ a medically proven form of contraception (e.g., condoms, oral contraceptives, etc)~* Any other condition that precludes participation according to the judgement of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Echinacea angustifolia (Type: EXPERIMENTAL): 20 mg tablet of Echinacea angustifolia root extract standardized for a specific alkamide profile, two tablets twice daily (total daily dose of 80 mg) for two weeks
- Placebo (Type: PLACEBO_COMPARATOR): Identical excipients as in the experimental arm, without the active ingredient

Based on this trial design, predict the completion outcome and termination type (if applicable).